In vivo bioequivalence study of Imatinib 100 mg capsule

Fasted state in vivo bioequivalence study for Imatinib 100 mg capsule manufactured by Avicenna Co. in comparison to German brand AQVIDA

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210519051345N6

Enrollment

Registered

2021-11-14

Start date

2021-11-06

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fasted state in vivo bioequivalence study.

Interventions

Intervention 1: Intervention group: In this group, a single dose of 100 mg imatinib capsule made by Avicenna company is taken orally and then after a washout period of one week, a 100 mg imatinib c

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: General Health including Liver, Heart and Kidney health Being at the age of 25-55 years old

Exclusion criteria

Exclusion criteria: Smoking History of cardiovascular disease History of liver and kidney disease Pregnancy Alcohol and drug addiction History of drug allergy

Design outcomes

Primary

Measure	Time frame
Drug Plasma Concentration. Timepoint: Blood samples will be obtained prior to dosing (baseline) and 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5, 4.0; 4.5, 6.0; 8.0; 12.0; 24.0; 48.0 and 72.0 h post-dose. Method of measurement: High performance liquid chromatography (HPLC).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParvin Zakeri-Milani

Tabriz University of Medical Sciences

pzakeri@tbzmed.ac.ir+98 41 3334 8801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026